# Drug Solubilization by Mixtures of Cyclodextrins: Additive and Synergistic Effects 

## Supporting Information

Christian Schönbeck ${ }^{\mathrm{a},{ }^{*}}$, Karina Gaardahl ${ }^{\mathrm{a}}$ and Bryan Houston ${ }^{\mathrm{a}}$<br>${ }^{\text {a }}$ Department of Science and Environment, Roskilde University, Universitetsvej 1, DK-4000, Roskilde, Denmark

## Modelling of the phase-solubility diagrams

Solving the system of equations 1-7 in the manuscript yields the concentrations of all species and thereby permits the theoretical construction of phase-solubility diagrams. In addition to these equations, some region specific restrictions are required. In region I and II, a solid phase of pure drug is present, and the concentration of free drug is therefore equal to its intrinsic solubility. In region II and III, a solid phase of higher-order complexes is present, and the concentrations of free CD and drug are constrained by the solubility product of the higher-order complex.

Analytical expressions for the concentrations of drug and cyclodextrin in the case of a 3:2 precipitation ratio are given in a previous paper. ${ }^{1}$ Analogous to these, the expressions in the case of a $2: 1$ precipitation ratio can be obtained. In the case of mixed CD samples, the theoretical phasesolubility diagram is derived below on page S4.

Derivation of equation 8 in the manuscript

As shown below, the solubility product of the 3:2 precipitate, $K_{S}^{32}=[L]^{3}[S]^{2}$, can be calculated from the drug concentration, $\mathrm{S}_{\mathrm{eq}}$, in region II.

In region II, the concentration of free drug is equal to the intrinsic solubility, so the mass conservation in eq. 1 in the manuscript can be written as:
$\mathrm{S}_{\mathrm{eq}}=\mathrm{S}_{0}+[\mathrm{LS}] \quad \Leftrightarrow$
$\mathrm{S}_{\mathrm{eq}}-\mathrm{S}_{0}=[\mathrm{LS}]$

Elimination of [LS] using eq. 6 in the manuscript yields:
$\mathrm{S}_{\mathrm{eq}}-\mathrm{S}_{0}=\mathrm{K} \cdot[\mathrm{L}] \cdot \mathrm{S}_{0}$

In region II, the solubility product may be written as:
$K_{S}^{32}=[L]^{3} S_{0}^{2}$

Isolating [L] from eq. S3 and inserting into eq. S4 yields the final expression:
$K_{S}^{23}=\frac{\left(S_{e q}-S_{0}\right)^{3}}{K^{3} \times S_{0}}$

## Derivation of equation 9 in the manuscript

The solubility product of the $2: 1$ precipitate, $K_{S}^{21}=[L]^{2}[S]$, can be calculated from the drug concentration, $\mathrm{S}_{\text {eq }}$, in region IIA. In region IIA, the concentration of free $\beta C D$ is equal to the intrinsic solubility of $\beta C D, L_{0}$, so eq. 6 in the manuscript can be written as:
$[\mathrm{LS}]=\mathrm{K} \cdot \mathrm{L}_{0} \cdot[\mathrm{~S}]$

Using eq. S6 to eliminate [LS] in eq. 1 in the manuscript yields:
$\mathrm{S}_{\mathrm{eq}}=[\mathrm{S}]+\mathrm{K} \cdot \mathrm{L}_{0} \cdot[\mathrm{~S}]=[\mathrm{S}]\left(1+\mathrm{K} \cdot \mathrm{L}_{0}\right)$

In region IIA, the solubility product may be written as:
$K_{S}^{21}=L_{0}^{2}[S]$

Isolating [S] from eq. S8 and inserting into eq. S7 yields:
$S_{e q}=\frac{K_{S}^{21}}{L_{0}^{2}}\left(1+K \times L_{0}\right)$

Rearranging eq. S9 yields the final expression:
$K_{S}^{21}=\frac{S_{e q} \times L_{0}^{2}}{K \times L_{0}+1}$

## Modelling the phase-solubility diagram with combinations of CDs

A notational clarification:

To provide a better overview of the sometimes long mathematical expression, a shorthand notation is used for $\beta C D$ and $\gamma \mathrm{CD}$, namely $\beta$ and $\gamma$. For instance, the concentration of free $\beta \mathrm{CD}$ is denoted by $[\beta]$, instead of $[\beta C D]$.

## Region I:

[L] can be isolated from equation 6 in the manuscript and inserted into equation 2 :
$L_{e q}=[L S]\left(1+\frac{1}{K \times[S]}\right) \Leftrightarrow$
$[L S]=\frac{K \times[S]}{1+K \times[S]} L_{e q}$

The solution concentration of a drug, $\mathrm{S}_{\mathrm{eq}}$, is the sum of free and complexed drug:
$S_{e q}=[S]+[\beta S]+[\gamma S]$

Here, the $1: 1$ complexes of drug with $\beta \mathrm{CD}$ and $\gamma \mathrm{CD}$ are denoted $[\beta \mathrm{S}]$ and $[\gamma \mathrm{S}]$, respectively.

In region $I$, the concentration of free $S$ is equal to its intrinsic solubility so [ S$]$ in equations S 12 and S 13 can be substituted with $\mathrm{S}_{0}$. Then the concentrations of the $1: 1$ complexes are calculated according to equation S12 and inserted into S13:
$S_{e q}=S_{0}+\frac{K_{\beta} s_{0}}{1+K_{\beta} s_{0}} \beta_{e q}+\frac{K_{\gamma} s_{0}}{1+K_{\gamma} s_{0}} \gamma_{e q}$
where $\beta_{\mathrm{eq}}$ and $\gamma_{\mathrm{eq}}$ denote the total concentrations of $\beta \mathrm{CD}$ and $\gamma \mathrm{CD}$, respectively, and $\mathrm{K}_{\beta}$ and $\mathrm{K}_{\gamma}$ are the equilibrium constant for formation of 1:1 complexes with $\beta C D$ and $\gamma \mathrm{CD}$, respectively.

Since no CD has precipitated in region $I$, the concentration of each CD is equal to the added amount:
$\boldsymbol{\beta}_{\text {eq }}=\boldsymbol{\beta}_{\boldsymbol{t}}$
$\gamma_{e q}=\gamma_{t}$

## Region II

Whenever a CD is in region II, the concentration of its $1: 1$ complexes can be derived as shown below. From the solubility product and the $1: 1$ binding constant:
$K_{S}^{21}=[\beta]^{2} \cdot[S]=\left(\frac{[\beta S]}{[S] \cdot K}\right)^{2} \cdot[S] \quad \Leftrightarrow$
$[\beta S]=K \sqrt{K_{S}^{21}[S]}$
Similarly, for a 3:2 complex:
$[\gamma S]=K \cdot \sqrt[3]{K_{S}^{32}[S]}$
[S] can be substituted with $\mathrm{S}_{0}$, and the expressions can be inserted into the mass balance in equation S13 to calculate the drug concentration, $\mathrm{S}_{\mathrm{eq}}$, in region II.

Inserting equations S18 and S19 into S11 yields the concentrations of CDs in region II:
$\beta_{e q}=K \sqrt{K_{S}^{21}[S]}\left(1+\frac{1}{K \times[S]}\right)$
$\gamma_{e q}=K \cdot \sqrt[3]{K_{S}^{32}[S]}\left(1+\frac{1}{K \times[S]}\right)$

The concentration of free $\mathrm{S},[\mathrm{S}]$, can be replaced by $\mathrm{S}_{0}$.

## Region III

Adaptation of equation 4 and 5 in the manuscript yields the following equations of mass conservation:
$\beta_{t}=\beta_{\text {eq }}+2 \times \beta_{2} S^{\text {prec }}$
$\gamma_{t}=\gamma_{e q}+3 \times \gamma_{3} S_{2}^{\text {prec }}$
$S_{t}=S_{e q}+\beta_{2} S^{\text {prec }}+2 \times \gamma_{3} S_{2}^{\text {prec }}$

By combining these three equations, the precipitated complexes can be eliminated:
$4 \gamma_{t}+3 \beta_{t}-6 S_{t}=4 \gamma_{e q}+3 \beta_{e q}-6 S_{e q}$

The concentrations on the right-hand side of equation S25 are given by equation S13 and:
$\beta_{e q}=[\beta]+[\beta S]$
$\gamma_{e q}=[\gamma]+[\gamma S]$

Insertion of these into the right-hand side of equation S25 yields:
$4 \gamma_{t}+3 \beta_{t}-6 S_{t}=4[\gamma]+3[\beta]-6[S]-2[\gamma S]-3[\beta S]$

No explicit analytical expression can be found for any of the concentrations on the right-hand side of equation S27. Instead they must be found by numerical solution of equation S27 together with the 4 equations for the 4 equilibrium constants, $K^{\beta}, K^{\gamma}, K_{S}^{21}$, and $K_{S}^{32}$. This forms a set 5 equations with 5 unknowns (the species concentrations in square brackets).

## Region IIA

This region resembles region II in that 3 solid phases are present: Solid $\beta$ CD, solid 2:1 $\beta$ CD:DX complex, and solid 3:2 $\gamma$ CD:DX complex. Concentrations of the 1:1 complexes can be calculated as in region II (equations S18 and S19) with the important difference that [S] is no longer equal to $\mathrm{S}_{0}$ but must be calculated from the solubility product of the $2: 1 \beta$ CD:DX complex:
$[S]=\frac{K_{S}^{21}}{[\beta]^{2}}$

The concentration of free $\beta C D,[\beta]$, is equal to the intrinsic solubility of $\beta C D, \beta_{0}$, as solid $\beta C D$ is present.

## Transitions between regions

To plot theoretical phase-solubility diagrams, the transitions between the regions must be calculated.

## Transition from region I to region II

Precipitation of higher-order complexes (Region II) will set in once the total concentration of CD in solution exceeds the total concentration of CD in solution in region II. Those concentrations are given by equations S20 and S21. In region $I$, all added $C D$ goes into solution $\left(\mathrm{CD}_{\mathrm{t}}=\mathrm{CD}_{\text {eq }}\right)$ so transitions from region I to region II will take place when:
$\beta_{t}=K \sqrt{K_{S}^{21} S_{0}}\left(1+\frac{1}{K \times S_{0}}\right)$
$\gamma_{t}=K \cdot \sqrt[3]{K_{S}^{32} S_{0}}\left(1+\frac{1}{K \times S_{0}}\right)$

## Transition from region II to region III

In the phase-solubility diagram in Figure 5 in the manuscript varied amounts of $\beta C D$ were added to vials containing constant amounts of DX and $\gamma \mathrm{CD}$. The transition calculated below is for the situation where both CDs are present as solid higher-order complexes in both region II and region III. We wish to find the amount of added $\beta \mathrm{CD}$ that corresponds to the point, at which all solid DX is depleted. Starting from equation S22, we wish to find the value of $\beta_{\mathrm{t}}$ at which there is no solid DX . We start by finding the amount of $\beta \mathrm{CD}$ in the precipitate to be inserted into equation S22. This is isolated from equation S24. Notice that no solid S is present in the mass conservation expressed in equation S24. This ensures that we find the transition from region II to region III.
$\beta_{2} S^{\text {prec }}=S_{t}-S_{e q}-2 \times \gamma_{3} S_{2}^{\text {prec }}$
$S_{\text {eq }}$ is eliminated by insertion of equation S13:
$\beta_{2} S^{\text {prec }}=S_{t}-[S]-[\beta S]-[\gamma S]-2 \times \gamma_{3} S_{2}^{\text {prec }}$

The amount of $\gamma \mathrm{CD}$ in the precipitate is isolated from equation S23 and inserted into equation S33:

$$
\begin{equation*}
\beta_{2} S^{\text {prec }}=S_{t}-[S]-[\beta S]-[\gamma S]-\frac{2}{3}\left(\gamma_{t}-\gamma_{e q}\right) \tag{S34}
\end{equation*}
$$

Now equation S34 can be inserted into equation S22:
$\beta_{t}=\beta_{e q}+2\left(S_{t}-[S]-[\beta S]-[\gamma S]-\frac{2}{3}\left(\gamma_{t}-\gamma_{e q}\right)\right)$

Expressing $\beta_{\mathrm{eq}}$ and $\gamma_{\mathrm{eq}}$ by equation S11 and reducing the expression yields:
$\beta_{t}=[\beta S]\left(\frac{1}{K^{\beta \cdot} \cdot S_{0}}-1\right)+[\gamma S]\left(\frac{4}{3} \frac{1}{K^{\gamma} \cdot S_{0}}-\frac{2}{3}\right)+2\left(S_{t}-S_{0}-\frac{2}{3} G_{a d d}\right)$

In equation $\mathrm{S} 36[\mathrm{~S}]$ has been replaced by $\mathrm{S}_{0} .[\mathrm{\beta S}]$ and $[\gamma \mathrm{S}]$ can be calculated by equations S 18 and S19 and inserted into equation S36 to give the transition from region II to III.

Transition to from region III to region IIA

In region III the concentration of free $\beta C D$ increases until it reaches its intrinsic solubility, $\beta_{0}$. The location of this transition is calculated using the expression for the transition from region II to region III (equation S36) as a starting point. Whereas the concentration of free S in equation S36 was equal to $S_{0}$, the concentration of free $S$ is now given by the $2: 1$ solubility product and the intrinsic solubility of $\beta C D$, as expressed by equation S29. The concentration of 1:1 complexes with $\beta C D$ can be expressed as:
$[\beta S]=K^{\beta} \times[D] \times \beta_{0}=K^{\beta} \times \frac{K_{s}^{21}}{\beta_{0}}$

The concentration of $1: 1$ complexes with $\gamma \mathrm{CD}$ is the same as in region II (S19). Inserting equation S37 and S19 into equation S36 and substituting all occurrences of $\mathrm{S}_{0}$ and $[\mathrm{S}]$ by equation S29, yields the following expression for the transition from region II to region IIA:
$\boldsymbol{\beta}_{t}=\beta_{0}-\frac{K^{\beta} K_{S}^{21}}{\beta_{0}}+K^{\gamma^{3}} \sqrt{\frac{K_{S}^{32} K_{S}^{21}}{\beta_{0}^{2}}}\left(\frac{4}{3} \frac{\beta_{0}^{2}}{K^{\gamma} K_{S}^{21}}-\frac{2}{3}\right)+2\left(S_{t}-\frac{K_{S}^{21}}{\beta_{0}^{2}}-\frac{2}{3} \gamma_{t}\right)$

## References

(1) Schönbeck, C.; Madsen, T. L.; Peters, G. H.; Holm, R.; Loftsson, T. Soluble 1:1 Complexes and Insoluble 3:2 Complexes - Understanding the Phase-Solubility Diagram of Hydrocortisone and $\gamma$-Cyclodextrin. Int. J. Pharm. 2017, 531 (2), 504-511.

